Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2022 - 01 - 24 save search
Digital Realty Announces Tax Treatment of 2021 Dividends
Published: 2022-01-24 (Crawled : 01:00) - prnewswire.com
DLR | $135.75 -0.5% 0.01% 1.1M
|
Finance
|
| O: -0.49%
H: 0.86%
C: -0.31%
treatment
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
Published: 2022-01-24 (Crawled : 00:00) - biospace.com/
MBIO | $0.384 10.92% 7.18% 270K
|
Health Technology
|
| O: -5.38%
H: 5.69%
C: 5.69%
FBIO | $1.77 0.57% 1.68% 250K
|
Health Technology
|
| O: -1.02%
H: 7.93%
C: 6.95%
mb-207 treatment application gene therapy therapy
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
Published: 2022-01-24 (Crawled : 22:00) - biospace.com/
ETNB | News | $9.16 -2.24% -2.07% 690K
|
Health Technology
|
| O: -2.79%
H: 2.67%
C: -1.44%
bio89 treatment expansion phase 1b trial 100 phase 1 report topline results positive results topline nash phase 2b
CareTrust REIT, Inc. Announces Tax Treatment of 2021 Dividends
Published: 2022-01-24 (Crawled : 15:30) - globenewswire.com
CTRE | $23.52 0.21% 0.81% 970K
|
Finance
|
| O: -0.52%
H: 0.14%
C: -0.24%
treatment trust
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor
Published: 2022-01-24 (Crawled : 15:00) - biospace.com/
ADIL | $2.32 3.57% 3.66% 1.2M
|
Health Technology
|
| O: -3.42%
H: 4.87%
C: 3.98%
ad04 treatment genetic als serotonin-3 order patent opioid biomarkers
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
VCYT | $18.86 -0.32% -0.26% 660K
|
Health Technology
|
| O: -3.0%
H: 11.05%
C: 10.59%
NSTG | News | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: -2.39%
H: 10.58%
C: 9.87%
treatment genomic cel lung cancer cancer
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
CDXS | $2.76 1.1% -0.74% 340K
|
Process Industries
|
| O: -9.93%
H: 7.09%
C: 6.37%
treatment fda rare drug disease rare pediatric disease designation orphan drug designation
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 10.0%
H: 7.27%
C: -1.82%
covid-19 treatment phase 2 trial covid tollovir
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Published: 2022-01-24 (Crawled : 13:30) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -2.11%
H: 2.77%
C: 2.72%
hzn-825 treatment phase 2 fibrosis phase 2b trial therapeutics enroll
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
LTRN | $5.99 -0.17% 0.0% 160K
|
Health Technology
|
| O: -9.09%
H: 3.23%
C: -1.13%
lp-184 treatment rare drug disease designation
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
TCRX | News 0 d | $6.75 -5.33% -5.47% 1.6M
|
Professional, Scientific, and T...
|
| O: -1.26%
H: 0.0%
C: -6.82%
tsc-100 new drug treatment fda ema clearance application drug therapeutics fda clearance 100 scan
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
KPTI | $1.38 25.46% 20.0% 3M
|
Health Technology
|
| O: 1.39%
H: 6.65%
C: 6.09%
treatment fda drug orphan drug syndros designation
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -3.62%
H: 7.66%
C: 6.27%
hpv16 new drug treatment fda clearance solid tumors application hpv drug cel fda clearance positive therapy biotech iot
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
SABS | $4.6 -5.74% -6.09% 3.6K
|
|
| O: -3.74%
H: 14.05%
C: 12.57%
sab-185 covid-19 treatment phase 2 trial therapeutics covid report positive phase 3 iot
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Published: 2022-01-24 (Crawled : 11:00) - biospace.com/
VRNA | $16.4 1.23% 1.28% 350K
|
Health Technology
|
| O: -6.52%
H: 0.0%
C: -2.93%
treatment trial phase 3 enroll
The Levi’s® 501® Original gets the NFT Treatment
Published: 2022-01-24 (Crawled : 09:00) - levistrauss.com
LEVI | $20.66 1.23% 0.15% 2.6M
|
Consumer Non-Durables
|
| O: -1.56%
H: 4.96%
C: 4.96%
treatment
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.